Processa Pharmaceuticals ... (PCSA)
Processa Pharmaceuticals Statistics
Share Statistics
Processa Pharmaceuticals has 5.27M shares outstanding. The number of shares has increased by 29.84% in one year.
| Shares Outstanding | 5.27M |
| Shares Change (YoY) | 29.84% |
| Shares Change (QoQ) | 0.34% |
| Owned by Institutions (%) | 4.19% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 10,018 |
| FTD / Avg. Volume | 0.45% |
Short Selling Information
The latest short interest is 2.01M, so 38.23% of the outstanding shares have been sold short.
| Short Interest | 2.01M |
| Short % of Shares Out | 38.23% |
| Short % of Float | 42.66% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.24 and the forward PE ratio is -0.29. Processa Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -0.24 |
| Forward PE | -0.29 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 1.71 |
| P/FCF Ratio | -0.26 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Processa Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.04.
| Current Ratio | 1.22 |
| Quick Ratio | 1.22 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,185,011.8 |
| Employee Count | 10 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -88.94% in the last 52 weeks. The beta is 1.04, so Processa Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.04 |
| 52-Week Price Change | -88.94% |
| 50-Day Moving Average | 0.38 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 38.9 |
| Average Volume (20 Days) | 2,226,090 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Net Income | -11.85M |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.62 |
Balance Sheet
The company has 1.19M in cash and 73.51K in debt, giving a net cash position of 1.12M.
| Cash & Cash Equivalents | 1.19M |
| Total Debt | 73.51K |
| Net Cash | 1.12M |
| Retained Earnings | -87.22M |
| Total Assets | 3.23M |
| Working Capital | 340.99K |
Cash Flow
In the last 12 months, operating cash flow was -11.25M and capital expenditures -3.24K, giving a free cash flow of -11.25M.
| Operating Cash Flow | -11.25M |
| Capital Expenditures | -3.24K |
| Free Cash Flow | -11.25M |
| FCF Per Share | -3.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PCSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PCSA is $6, which is 2300% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 2300% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jan 22, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Jan 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -49.51 |
| Piotroski F-Score | 1 |